Two Main Cancer Biomarkers as Molecular Targets of Binase Antitumor Activity.

Elena Dudkina, Vera Ulyanova, Violetta Asmandiyarova, Valentina Vershinina, Olga Ilinskaya

Abstract read

In one paragraph

Article in BioMed research international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Novel Organomineral Complex with Prolonged Antitumor Action.International journal of molecular sciences · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elena DudkinaDepartment of Microbiology, Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan 420008, Russia.ORCID https://orcid.org/0000-0002-2817-1384

Vera UlyanovaDepartment of Microbiology, Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan 420008, Russia.ORCID https://orcid.org/0000-0003-1768-3314

Violetta AsmandiyarovaDepartment of Microbiology, Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan 420008, Russia.

Valentina VershininaDepartment of Microbiology, Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan 420008, Russia.ORCID https://orcid.org/0000-0001-5712-3325

Olga IlinskayaDepartment of Microbiology, Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, Kazan 420008, Russia.ORCID https://orcid.org/0000-0001-6936-2032

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is frequently coupled with the disturbance of key signaling pathways. Aberrant activation of the mitogen-activated protein kinase (MAPK) signaling cascade, occurring in over 85% of cancers, is mainly caused by the genetic alterations of its main components-oncogenes EGFR and RAS, and plays a crucial role in cell fate. The importance of EGFR and RAS proteins in a variety of tumors suggests that they would be good therapeutic targets, but at present, no effective targeted therapy against these two oncogenes has been proven. Here, we show that ribonuclease from

Indexed as

EndoribonucleasesNeoplasmsErbB Receptorsras ProteinsRibonucleasesEndoribonucleasesErbB Receptorsras ProteinsRibonucleasesribonuclease T(2)

Identifiers

PMID38374954

DOI10.1155/2024/8159893

PMCPMC10876309

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.